Pharma Stocks Soar 5% as US Senate Passes Biosecure Act, India Benefits

• US Senate passes 'Biosecure Act', part of NDAA fiscal 2026, barring Chinese biotech from federal funding.
• Indian pharma stocks jump, Nifty Pharma index up 0.65%, as India is seen as a key beneficiary.
• Wockhardt leads gainers with 5% jump; Divi's Laboratories, Laurus Labs also see significant rises.
• Act aims to reduce China's influence in biotech supply chains and prevent espionage.
• Industry leaders like Nandini Piramal view it as a long-term opportunity for India.

Why It Matters: US Biosecure Act boosts Indian pharma stocks, positioning India as a key alternative to China.